1 / 20

Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States

Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States.

louvain
Download Presentation

Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States E. J. Bini, MD, MPH; S. Kritz MD; L.S. Brown, MD, MPH; J. Robinson, MEd; D. Alderson, MS; P. McAuliffe, MBA, LADC; C. Smith, MD; J. Rotrosen, MD; and the NIDA Clinical Trials Network Infections Study (CTN-0012) Team NYU School of Medicine and VA Hospital, NY, NY; Addiction Research & Treatment Corp, Brooklyn, NY; Nathan Kline Institute, Orangeburg, NY; NYS Psychiatric Institute, NY, NY; Connecticut Renaissance, Inc., Norwalk, CT; Mount Sinai School of Medicine, NY, NY

  2. Acknowledgements • Research Supported by the National Institute on Drug Abuse (NIDA) as part of a Cooperative Agreement (1U10DA013046) with the NIDA CTN; and other Protocol Team members consisting of: • Randy Seewald, MD; Frank McCorry, PhD; Dennis McCarty, PhD; Donald Calsyn, PhD; Leonard Handelsman, MD; Steve Kipnis, MD • Al Hassen, MSW; Karen Reese, CAC-AD; Sherryl Baker, PhD • Shirley Irons; Kathlene Tracy, PhD

  3. Acknowledgements • There are no financial interests or disclosures to report for any of the authors involved in this project

  4. Background • HBV and HCV are major causes of morbidity and mortality in the U.S. • Substance abusers are disproportionally affected by HBV and HCV, and these individuals are largely responsible for sustaining the viral hepatitis epidemic in the U.S. • Despite the potential role of substance abuse treatment programs in reducing transmission of viral hepatitis, surprisingly little is known about HBV and HCV health services offered by drug treatment programs in the U.S.

  5. Primary Objectives • To describe the: • Specific types of HBV and HCV testing available • Range of HCV-related services offered by substance abuse treatment programs • Availability of HCV treatment • To determine whether HCV-related health services differ between: • Programs that do and those that do not have clear guidelines for hepatitis testing • Methadone and non-methadone programs

  6. Study Design and Study Population • Study design • Cross-sectional survey • Descriptive & exploratory • Study population • Treatment program administrators of drug treatment programs in the U.S.

  7. Study Sites • New York Node:New York University, New York, NY • South Carolina Node:Medical University of South Carolina, Charleston, SC • Florida Node:University of Miami, Coral Gables, FL • Great Lakes Node:Wayne State University, Detroit, MI • Ohio Valley Node:University of Cincinnati, Cincinnati, OH • Rocky Mountain Node:University of CO Health Sciences Center, Denver, CO • New England Node:Yale University, New Haven, CT • Delaware Valley Node:University of Pennsylvania, Philadelphia, PA • Mid-Atlantic Node:Johns Hopkins Univ., Baltimore, MD; Medical College of Virginia, Richmond • Pacific Region Node:University of California at Los Angeles, CA • Oregon Node:Oregon Health Sciences University, Portland, OR • Washington Node:University of Washington, Seattle, WA • Long Island Node:NY State Psychiatric Institute, New York, NY • North Carolina Node:Duke University, Raleigh/Durham, NC • Southwest Node:University of New Mexico, Albuquerque, NM • Northern New England Node:McLean Hospital, Belmont, MA • California-Arizona Node:University of California at San Francisco, CA

  8. Drug Abuse Treatment Clinical Trials Network 17 Nodes with 116 Community Treatment Agencies Reaching into 26 States! Seattle Portland New York City Detroit Boston New Haven Denver Long Island Philadelphia Cincinnati San Francisco (CA/AZ Node) Baltimore/Richmond Raleigh/ Durham Albuquerque Los Angeles Charleston Miami CTN Study Sites

  9. Study Procedures • Expedited IRB Approval • Waiver of Informed Consent • Training for Node Protocol Managers • Information Sheet In Lieu of Informed Consent • Survey Administration • Paper or electronic • Central data acquisition

  10. Administrator Surveys Administrator completes survey online or mails to Data Center; Administrator enters contact information for Clinicians Contact CTP Directors for Treatment Program and Administrator contact information Ensure IRB approval Survey materials mailed to Administrators Data Center contacts Administrators that have not completed the survey or Clinician contact information within 30 days Node Protocol Manager contacts Administrators that have not responded within two weeks Data Center contacts Administrators to resolve any data queries After four weekly attempts, Administrators flagged as non-responders by the Data Center Node Protocol Managers contact non-responder Administrators weekly For Administrators that refuse to participate or still have not responded after two additional weeks, the Node Protocol Manager alerts the Node Principal Investigator

  11. RESULTS • 319 treatment program administrators surveyed • 269 individuals (84.3%) from geographically diverse locations in the U.S. returned completed questionnaires

  12. Characteristics of the Substance Abuse Treatment Programs Surveyed (1) *Responses were not mutually exclusive for this item

  13. Characteristics of the Substance Abuse Treatment Programs Surveyed (2)

  14. HCV Training of Medical and Non-Medical Staff in Substance Abuse Treatment Programs

  15. HBV Testing Offered by Drug Treatment Programs

  16. HCV Testing and Hepatitis A and B Virus Vaccinations Offered by Drug Treatment Programs

  17. HCV Services Offered by Drug Treatment Programs

  18. Proportion of Substance AbusePrograms That Offered HCV Testing And Hepatitis Vaccination Services According to the Presence or Absence of Clear or Somewhat Clear HCV Testing Guidelines

  19. HCV Services Offered by Methadone and Non-Methadone Substance Abuse Treatment Programs P <0.01 for all comparisons between methadone and non-methadone programs

  20. Conclusions • Despite the importance of substance abuse in sustaining the viral hepatitis epidemic in the U.S., many substance abuse treatment programs do not offer comprehensive • HBV or HCV testing • HCV-related health services • HCV treatment • Hepatitis vaccination services • Public health interventions to improve access to hepatitis testing, treatment, and prevention for substance abusers are needed

More Related